Skip to main content

Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET

Written by Customer Service on . Posted in Public Companies.

ATLANTA, July 11, 2022 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company has been invited to present at the Women’s Health Panel Discussion, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, July 13th, 2022 at 11:00 a.m. ET.

During this on-demand virtual event, Kathy Lee-Sepsick, Founder, President and Chief Executive Officer, will participate in the panel detailed below:

Panel title: “A tipping point in women’s health – does the SCOTUS outcome change the paradigm in contraception?”

Panel Description: “This is the most critical time in women’s health in decades, perhaps ever. The Supreme Court decision to overturn Roe v. Wade continues to reverberate across the country. As a result, the discussion around contraception, contraceptive options, access, issues with pharmacy benefit managers and women’s reproductive health as a space, have all accelerated to the forefront of discussion from the media and general public, all the way to the White House. Please Join us July 13, 2022, at 11:00 am for a panel discussion with key players in the contraception space; Agile Therapeutics, Dare Bioscience and Femasys.”

Panel day/ time: Wednesday, July 13th 2022 at 11 a.m. ET.

This conference will be live on M-Vest. To listen to the panel discussion, register to become an M-Vest member here.

About Femasys

Femasys Inc. is a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

Contacts:

Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com

Femasys Inc.

Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.